mTOR/JAK inhibitor combination therapy

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9993480
SERIAL NO

13399274

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided herein is a combination therapy comprising an mTOR inhibitor and a JAK inhibitor. The combination therapy is useful for the treatment of a variety of cancers, including myeloproliferative neoplasms. The combination therapy is also useful for the treatment of any number of JAK-associated diseases.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NOVARTIS PHARMA AGBASEL
INCYTE CORPORATION1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bogani, Costanza Florence, IT 2 221
Guglielmelli, Paola Florence, IT 2 98
Vannucchi, Alessandro M Florence, IT 2 221

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 12, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 12, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00